Shots:

• Eureka and MSK are eligible to receive up front and ~$1B as development- regulatory and sales milestone along with royalties on net sales. Sanofi gets exclusive rights to the GPRC5D binder for non-CAR use
• Eureka discovered the GPRC5D binding domain using its E-ALPHA Abs discovery platform- under its collaboration with MSK
• Additionally- targeting GPRC5D may improve the durability of response from current therapies and improves the long-term clinical benefits for patients

  Ref: Businesswire | Image: Eureka Therapeutics